306 related articles for article (PubMed ID: 23704211)
1. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
Baird JR; Fox BA; Sanders KL; Lizotte PH; Cubillos-Ruiz JR; Scarlett UK; Rutkowski MR; Conejo-Garcia JR; Fiering S; Bzik DJ
Cancer Res; 2013 Jul; 73(13):3842-51. PubMed ID: 23704211
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract][Full Text] [Related]
3. Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.
Fox BA; Sanders KL; Rommereim LM; Guevara RB; Bzik DJ
PLoS Genet; 2016 Jul; 12(7):e1006189. PubMed ID: 27447180
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Fox BA; Sanders KL; Chen S; Bzik DJ
Trends Parasitol; 2013 Sep; 29(9):431-7. PubMed ID: 23928100
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
[TBL] [Abstract][Full Text] [Related]
6. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
7. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Barber A; Rynda A; Sentman CL
J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
[TBL] [Abstract][Full Text] [Related]
8. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
Baird JR; Byrne KT; Lizotte PH; Toraya-Brown S; Scarlett UK; Alexander MP; Sheen MR; Fox BA; Bzik DJ; Bosenberg M; Mullins DW; Turk MJ; Fiering S
J Immunol; 2013 Jan; 190(1):469-78. PubMed ID: 23225891
[TBL] [Abstract][Full Text] [Related]
9. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
10. Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.
Zorgi NE; Galisteo AJ; Sato MN; do Nascimento N; de Andrade HF
Med Microbiol Immunol; 2016 Aug; 205(4):297-314. PubMed ID: 26732075
[TBL] [Abstract][Full Text] [Related]
11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
12.
Chen J; Liao W; Peng H
Front Cell Infect Microbiol; 2022; 12():959300. PubMed ID: 36118042
[TBL] [Abstract][Full Text] [Related]
13. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
Scarlett UK; Cubillos-Ruiz JR; Nesbeth YC; Martinez DG; Engle X; Gewirtz AT; Ahonen CL; Conejo-Garcia JR
Cancer Res; 2009 Sep; 69(18):7329-37. PubMed ID: 19738057
[TBL] [Abstract][Full Text] [Related]
14. VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.
Tiper IV; Temkin SM; Spiegel S; Goldblum SE; Giuntoli RL; Oelke M; Schneck JP; Webb TJ
Clin Cancer Res; 2016 Aug; 22(16):4249-58. PubMed ID: 27076627
[TBL] [Abstract][Full Text] [Related]
15. Control of human mesothelin-expressing tumors by DNA vaccines.
Chang CL; Wu TC; Hung CF
Gene Ther; 2007 Aug; 14(16):1189-98. PubMed ID: 17581599
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
17. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.
Chen YL; Chang MC; Chen CA; Lin HW; Cheng WF; Chien CL
PLoS One; 2012; 7(10):e47190. PubMed ID: 23082146
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication.
Gigley JP; Fox BA; Bzik DJ
J Immunol; 2009 Jan; 182(2):1069-78. PubMed ID: 19124750
[TBL] [Abstract][Full Text] [Related]
19. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
